Lyon Joseph Douglas, SR, reported a transaction classified as grant at CORCEPT THERAPEUTICS INC involving 216.000000 shares for an estimated $12759.12. Reported holdings after the transaction were 8793.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
Form 4 relationship flags and nearby filing context
See Remarks
These shares were withheld by the Issuer in order to satisfy certain withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
The closing price on February 28, 2025 was used to calculate the withholding obligation.
Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the R…
The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 I…
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-y…
The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.58 to $61.055 per share. Information on the exact number of shares sold at each s…
Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.
Fully exercisable.
0 other filings
0 recent txs